// App-Quantinova.ai

1817 : Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry

Researchers

Presenter

  • Denis Choquette

Principal Investigators

  • L Bessette

  • E Alemao

  • B Haraoui

  • F Massicotte

  • M Mtibaa

  • E Muratti

  • Jean-Pierre Pelletier

  • R Postema

  • Jean-Pierre Raynauld

  • M-A Rmillard

  • D Sauvageau

  • A Turcotte

  • Villeneuve

  • L Coupal

Medical Centers

  • Rhumatology, Institut de recherche en rhumatologie de Montreal IRRM, Montreal, QC, Canada

  • Centre -Osteoporose et de Rhumatologie de Quebec CORQ, Quebec, QC, Canada

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Institut de Recherche en Rhumatologie de Montreal, Montreal, Canada

  • Bristol-Myers Squibb, Montreal, QC, Canada

  • Bristol-Myers Squibb, Uxbridge, United Kingdom

  • Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada

  • Rhumatology, Institut de recherche en rhumatologie de Montreal IRRM, Montreal, QC, Canada

  • Centre de l'Ostéoporose et de Rhumatologie de Québec, Québec, QC, Canada

  • Institut de Recherche en Rhumatologie de Montreal, Montreal, Canada

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved